AzTrials
AzTrials

Solid Tumor and Hematologic MalignanciesPhase 2SIGNATURENCT01885195

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

A Phase 2 study testing MEK162 in people with Solid Tumor and Hematologic Malignancies, run by Pfizer at 68 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Solid Tumor and Hematologic Malignancies
What is being tested?
MEK162
Could I receive a placebo?
No, everyone receives an active treatment
How many people
110 participants
Where
68 sitesUnited States
Study dates
10 Oct 2013to 11 Apr 2017
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient has a confirmed diagnosis of a select solid tumor (except for primary diagnosis of pancreatic cancer, biliary cancer, colorectal cancer, low grade serous ovarian cancer, melanoma) or hematologic malignancy (except for primary diagnosis of chronic myelomonocytic leukemia).
  • Patients must be pre-identified as having a tumor with a mutation in RAF, RAS, NF1 or MEK at a CLIA certified laboratory
  • Patient must have received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
  • Patient must have progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.
  • Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Who cannot join

  • Patient has received prior treatment with MEK162.
  • Patients with primary CNS tumor or CNS tumor involvement
  • History of retinal degenerative disease
  • History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO)
  • Any ophthalmopathy visible at screening that would be considered a risk factor for CSR or RVO by the ophthalmologist
  • Patients who have neuromuscular disorders that are associated with elevated CK

Trial locations and contacts

68 sites in 1 country.

68 sites in 1 country

United States68 sites
  • New Mexico Cancer Care Alliance Oncology Dept

    Albuquerque, New Mexico, 87106

  • Alaska Oncology and Hematology AOH (2)

    Anchorage, Alaska, 99508

  • University Cancer & Blood Center, LLC

    Athens, Georgia, 30607

  • St. Charles Cancer Center

    Bend, Oregon, 97701

  • St. Luke's Hospital and Health Network St Luke's (2)

    Bethlehem, Pennsylvania

  • Rocky Mountain Cancer Centers USOR

    Boulder, Colorado, 80304

  • University of North Carolina Chapel Hill Physician Office Building

    Chapel Hill, North Carolina, 27514

  • Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology

    Chattanooga, Tennessee, 37404

  • Lurie Children's Hospital of Chicago Developmental Therapeutics

    Chicago, Illinois, 60611

  • Cleveland Clinic Foundation Cleveland Clinic (19)

    Cleveland, Ohio, 44195

  • Ohio State University Medical Center Comprehensive Cancer Center

    Columbus, Ohio, 43221

  • Metro MN CCOP - Coon Rapids

    Coon Rapids, Minnesota, 55433

  • Texas Oncology Presbyterian Hospital (3)

    Dallas, Texas, 75246

  • Texas Oncology Texas Oncology - Denton

    Dallas, Texas, 75246

  • Texas Oncology Austin Midtown

    Dallas, Texas, 75251

  • Texas Oncology Texas Oncology - Midland

    Dallas, Texas, 75251

  • Sammons Cancer Center - Texas Oncology Sammons Cancer Center (10)

    Dallas, Texas, 78246

  • Duke University Medical Center Seeley G. Mudd Bldg.

    Durham, North Carolina, 27710

  • Willamette Valley Clinical Studies Cancer Institute & Res. Ctr.

    Eugene, Oregon, 97404

  • Virginia Cancer Specialists, PC Virginia Cancer Specialists

    Fairfax, Virginia, 22031

  • Sanford Research/USD-Fargo Sanford Hematology Oncology

    Fargo, North Dakota, 58122

  • Highlands Oncology Group Highlands Oncology Group (22)

    Fayetteville, Arkansas, 72703

  • Florida Cancer Specialists Florida Cancer Specialists (31

    Fort Myers, Florida, 33901

  • Cancer and Hematology Centers of West Michigan Dept. of Oncology

    Grand Rapids, Michigan, 49546

  • Memorial Cancer Institute Memorial Healthcare System

    Hollywood, Florida, 33021

  • Oncology Consultants Oncology Group

    Houston, Texas, 77024

  • MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)

    Houston, Texas, 77030

  • Indiana University Indiana Univ. - Purdue Univ.

    Indianapolis, Indiana, 46202

  • University of Iowa Hospitals & Clinics Regulatory Contact 2

    Iowa City, Iowa, 52242

  • Cancer Specialists of North Florida

    Jacksonville, Florida, 32256

  • Glacier View Research Institute - Cancer Oncology Dept

    Kalispell, Montana, 59901

  • Research Medical Center Research Med Center (2)

    Kansas City, Missouri, 64132

  • Kadlec Clinic Hematology and Oncology Kadlec Clinic Hematology & Onc

    Kennewick, Washington, 99336

  • Providence Regional Cancer System

    Lacey, Washington, 98503

  • Comprehensive Cancer Centers of Nevada CCC of Nevada (21)

    Las Vegas, Nevada, 89109

  • The West Clinic Dept. of the West Clinic

    Memphis, Tennessee, 38120

  • Mt. Sinai Comprehensive Cancer Center

    Miami Beach, Florida, 33140

  • Medical College of Wisconsin Cancer Center

    Milwaukee, Wisconsin, 53226

  • University of South Alabama / Mitchell Cancer Institute Univ South Alabama

    Mobile, Alabama, 36688

  • Intermountain Medical Center Intermountain Healthcare

    Murray, Utah, 84157

  • Sarah Cannon Research Institute Sarah Cannon Research Inst (51

    Nashville, Tennessee, 37203

  • West Penn Allegheny Oncology Network

    Natrona Heights, Pennsylvania, 15065

  • Cancer Institute of New Jersey CINJ

    New Brunswick, New Jersey, 08901

  • Yale University School of Medicine Yale Cancer Center

    New Haven, Connecticut, 06511

  • Whittingham Cancer Center Norwalk Hospital

    Norwalk, Connecticut, 06856

  • Eastern Connecticut Hematology & Oncology Associates Dept. of ECHO

    Norwich, Connecticut, 06360

  • Ocala Oncology Center Dept. of Ocala Oncology Center

    Ocala, Florida, 34474

  • Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4

    Ocoee, Florida

  • Oncology Specialists, SC Onc Specialists

    Park Ridge, Illinois, 60068-0736

  • Illinois Cancer Care IL. Cancer Care

    Peoria, Illinois, 61615-7828

  • Arizona Oncology Associates AZ Oncology Assoc.

    Phoenix, Arizona

  • Arizona Oncology Associates HOPE Division

    Phoenix, Arizona

  • PCR Oncology

    Pismo Beach, California, 93449

  • Northwest Cancer Specialists Vancouver Cancer Center

    Portland, Oregon, 97210

  • Oregon Health & Science University Oregon Health & Science U (56)

    Portland, Oregon, 97239

  • Medical Oncology & Hematology Associates of Northern VA Med Onc Hem Northern VA

    Reston, Virginia, 20190

  • Maryland Oncology Hematology, P.A. Oncology Hematology

    Rockville, Maryland, 20850

  • University of California Davis Cancer Center UC Davis Cancer (3)

    Sacramento, California, 95817

  • Cancer Care Centers of South Texas / HOAST CCC of So. TX-San Antonio (3)

    San Antonio, Texas, 78229

  • Arizona Oncology Associates PC- NAHOA

    Sedona, Arizona, 86336

  • Washington University School of Medicine Washington University (16)

    St Louis, Missouri, 63110

  • Hematology Oncology PC Stamford Hospital

    Stamford, Connecticut, 06902

  • MultiCare Health System Institute for Research & Innovation MultiCare

    Tacoma, Washington, 98405

  • Northwest Medical Specialties NW Medical Specialties

    Tacoma, Washington, 98405

  • New York Oncology Hematology, P.C. NYOH Latham

    Troy, New York, 12180

  • Tyler Cancer Center Dept.ofTylerCancerCtr. (2)

    Tyler, Texas, 75702

  • Deke Slayton Cancer Center Deke Slayton Cancer Center (2)

    Webster, Texas, 77598

  • Abington Hematology Oncology Associates, Inc Abington Hem Onc Assoc (5)

    Willow Grove, Pennsylvania, 19090

Other trials in United States

About this study

Official title: Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors

The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

Read the detailed description

This is a phase II, open label study to determine the efficacy and safety of treatment with MEK162 in patients with a diagnosis of select solid tumors or hematological malignancies that have been pre-identified (prior to study consent) to have activations of the RAS/RAF/MEK pathway and whose disease has progressed on or after standard treatment.

Genomic profiling is becoming more accessible to patients and their physicians. This is a signal-seeking study to match patients with mutations in RAF, RAS, NF1 or MEK to the ATP-noncompetitive MEK 1/2 inhibitor, MEK162. Pre-identification of these mutations or activations in the pathway will be performed locally at a CLIA certified laboratory prior to screening for participation on the trial.

Once the patient has been identified, treating physicians who are qualified investigators may contact Novartis to consider enrollment in this study. For the purpose of this study, genomic profiling is not considered part of screening. Informed consent must be signed before any screening activities take place. Once eligibility (screening criteria met) has been confirmed by Novartis, the patient will initiate therapy with single agent MEK162. The patient may not receive any additional anti-cancer therapy during treatment with MEK162.

Patients will continue to receive study treatment until disease progression (assessed by RECIST 1.1 or appropriate hematologic response criteria), unacceptable toxicity, death or discontinuation from study treatment for any other reason (e.g., withdrawal of consent, start of a new anti-neoplastic therapy or at the discretion of the investigator), otherwise known as End of Treatment. All patients who discontinue from study treatment due to disease progression must have their progression clearly documented.

Disease assessment (per RECIST 1.1 or appropriate hematological response criteria) will be performed every 8 weeks (±4 days) after first dose of study drug (Day 1 of every odd cycle), until disease progression or end of treatment, whichever occurs first. The frequency of disease assessment may be reduced to every 12 weeks for patients who have at least 4 post-baseline disease assessments and are clinically stable (except AML and MM patients). Scans will be assessed locally by the investigator. After discontinuation of treatment, patients, regardless of reason for treatment discontinuation, will be followed for safety for 30 days after the last dose.

All patients will be followed for survival status every 3 months for 2 years after the last patient has enrolled in the study regardless of treatment discontinuation reason (except if consent is withdrawn or patient is lost to follow-up.)

Being tested
MEK162
Keywords
RAS, RAF, MEK, NF1, MEK162, signature, papillary thyroid, small intestine, bladder, esophagus, lung cancer, NSCLC, acute myelogenous leukemia, AML
Medical subject headings
Hematologic Neoplasms, Noonan Syndrome 5, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Leukemia, Myeloid, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MEK162Drug

    MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.

Study groups in NCT01885195
Study groupRoleWhat they receive
MEK162ExperimentalMEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
Receives: Drug: MEK162

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    CBR: participants with complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks. As per RECIST 1.1, CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to less than (<) 10 millimeter (mm); PR: at least a 30 percent (%) decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of >=1 new target or non-target lesions.

    Measured: Week 16

  2. CBR for Hematologic Tumors at Week 16: Multiple Myeloma

    CBR: participants with stringent complete response(sCR), CR, very good partial response(VGPR), PR/SD for at least 16 weeks. For hematologic tumors (multiple myeloma), sCR: negative immunofixation on serum, urine, disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow plus normal free light chain(FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry/immunofluorescence; CR: negative immunofixation on the serum, urine, disappearance of any soft tissue, plasmacytomas and <5% plasma cells in bone marrow; VGPR: serum,urine M-component detectable by immunofixation but not on electrophoresis or>=90% reduction in serum M-component plus urine M-component <100 mg/24 hr; PR: >50% reduction of serum M-protein and reduction in 24hr urinary M-protein by >90%/to <200 mg/24 hr; SD: not meeting criteria for CR, VGPR, PRor PD; PD: increase of >25% from lowest response value in serum M-component, urine M-component and bone marrow plasma cell percentage.

    Measured: Week 16

  3. CBR for Hematologic Tumors at Week 16: Acute Myeloid Leukemia

    CBR: participants with complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR) and no resposne for at least 16 weeks. For hematologic tumors (acute myeloid leukemia); CR: as bone marrow- < 5% blasts, no blasts with auer rods, peripheral blood- neutrophils ≥1.0*10^9/L and/or platelets ≥100*10^9/L, ≤1% blasts, no evidence of extramedullary disease (such as CNS or soft tissue involvement), transfusion independent; CRi: all the CR criteria were involved but platelet and neutrophil transfusions were also allowed; PR: bone marrow- 50% or greater decrease (absolute range 5-25% blasts), < 5% of blasts contain auer rods, peripheral blood- neutrophils <1.0*10^9/L and/or platelets <100*10^9/L, no evidence of extramedullary disease; no response: in case a patient did not achieve CR, CRi, PR or relapse for an individual response assessment.

    Measured: Week 16

Secondary outcomes (12)
  1. Overall Response Rate (ORR) as Per RECIST Version 1.1

    ORR: percentage of participants with a best overall response (BOR) of CR or PR as assessed per RECIST version 1.1. BOR: the best response recorded from the start of the treatment until disease progression (PD). CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to less than <10 mm; PR: at least a 30 % decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of >=1 new target or non-target lesions.

    Measured: From the start of the treatment until disease progression (maximum up to 19.4 months)

  2. ORR for Hematologic Tumors: Multiple Myeloma

    ORR: percentage of participants with sCR, CR, VGPR or PR. For hematologic tumors (multiple myeloma), sCR: negative immunofixation on the serum, urine, disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; CR: CR: negative immunofixation on the serum, urine, disappearance of any soft tissue, plasmacytomas and <5% plasma cells in bone marrow; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis or greater than equal to >=90% reduction in serum M-component plus urine M-component <100 mg per 24hour (hr); PR: >50% reduction of serum M-protein and reduction in 24 hr urinary M-protein by >90% or to <200 mg/24 hr.

    Measured: From the start of the treatment until disease progression (maximum up to 19.4 months)

  3. ORR for Hematologic Tumors: Acute Myeloid Leukemia

    ORR: participants with complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR) and no resposne for at least 16 weeks. For hematologic tumors (acute myeloid leukemia); CR: as bone marrow- < 5% blasts, no blasts with auer rods, peripheral blood- neutrophils ≥1.0*10^9/L and/or platelets ≥100*10^9/L, ≤1% blasts, no evidence of extramedullary disease (such as CNS or soft tissue involvement), transfusion independent; CRi: all the CR criteria were involved but platelet and neutrophil transfusions were also allowed; PR: bone marrow- 50% or greater decrease (absolute range 5-25% blasts), < 5% of blasts contain auer rods, peripheral blood- neutrophils <1.0*10^9/L and/or platelets <100*10^9/L, no evidence of extramedullary disease.

    Measured: From the start of the treatment until disease progression (maximum up to 19.4 months)

  4. Progression-free Survival (PFS) as Per RECIST Version 1.1

    PFS was defined as the time from the date of first dose to the date of first documented PD or relapse or death due to any cause. PD: at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of >=1 new target or non-target lesions was also considered progression. PFS data was censored at date of last adequate tumor assessment.

    Measured: From the date of first dose to the date of the first documented PD, censored date or death (maximum up to 19.4 months)

  5. Overall Survival (OS)

    OS was defined as the time from the date of first dose to the date of death due to any cause. If a participant was not known to have died, survival time was censored at the date of last contact.

    Measured: From the date of first dose to the date of death due to any cause (maximum up to 19.4 months)

  6. Duration of Response (DOR) as Per RECIST Version 1.1

    DOR was defined as the time from the first documented response (CR or PR) to the date of first documented disease progression, relapse or death due to any cause. As per RECIST 1.1, CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to <10 mm; PR: at least a 30% decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; PD: at least a 20% increase in sum of diameter of all measured target lesions, taking as reference smallest sum of diameter of all target lesions recorded at or after baseline, sum was also an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. Appearance of >=1 new target or non-target lesions. The DOR was determined only in participants whose best response was PR or greater.

    Measured: From the first documented response (CR or PR) to the date of the first documented PD or death (maximum up to 19.4 months)

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03

    Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated. Treatment-emergent adverse events were defined as new or worsening events that were collected from first study treatment date to last treatment date +30 days. AEs of all grades were reported.

    Measured: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  8. Number of Participants With Vital Sign Abnormality of Greater Than or Equal to (>=) Grade 3 as Per CTCAE v4.03

    Vital signs included hypertension, hypotension and weight decreased were reported. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated. Participants with grade 3 or higher vital sign abnormality are reported.

    Measured: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  9. Number of Participants With Electrocardiogram (ECG) Abnormalities

    ECG abnormalities criteria included: 1) QTc interval adjusted according to Bazett formula (QTcF) in millisecond (msec): greater than equal to (>=) 450 to less than (<) 480, >=480 to <500, >=500, increase from baseline >=30, increase from baseline >=60; 2) QTc interval adjusted according to Fridericia formula (QTcB) (msec): >=450 to <480, >=480 to <500, >=500, increase from baseline >=30, increase from baseline >=60. 3) QT (msec): >=450 to <480, >=480 to <500, >=500, increase from baseline >=30, increase from baseline >=60.

    Measured: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  10. Number of Participants With Shift From Baseline in Clinical Laboratory - Hematology Parameters

    Laboratory parameters included hematological and biochemistry parameters. Hematological parameters included neutrophils, platelets, prothrombin time, activated partial thromboplastin time, INR, fibrinogen. Number of participants with hematological abnormalities by grades (as per Common Terminology Criteria for Adverse Events (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Participants with a grade shift of 3 or more from baseline are reported in this outcome measure.

    Measured: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  11. Number of Participants With Shift From Baseline in Clinical Laboratory - Biochemistry Parameters

    Laboratory parameters included hematological and biochemistry parameters. Biochemistry parameters included: creatinine, phosphorus, albumin, gamma-glutamyl transferase, aspartate transaminase, alanine aminotransferase, alkaline phosphatase, total bilirubin, uric acid, amylase, lipase, creatine kinase, total cholesterol and triglycerides. Number of participants with biochemistry test abnormalities by grades (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Participants with a grade shift of 3 or more from baseline are reported in this outcome measure.

    Measured: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

  12. Number of Participants With Shift From Baseline in Cardiac Imaging

    Number of Participants With Shift From Baseline in Cardiac Imaging were reported.

    Measured: From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2013 (estimated)
  2. Study start10 Oct 2013
  3. Primary completion1 Oct 2015
  4. Study completion11 Apr 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01885195
Sponsor's protocol ID
CMEK162AUS11
Other IDs
C4211007
Acronym
SIGNATURE
Status last verified
Feb 2021
First submitted
20 Jun 2013
Last updated
21 Feb 2021
Data monitoring committee
No
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B. Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. J Natl Compr Canc Netw. 2018 Sep;16(9):1035-1040. doi: 10.6004/jnccn.2018.7043.

    PubMed 30181415

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing MEK162 in people with Solid Tumor and Hematologic Malignancies, run by Pfizer at 68 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 68 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (time frame: Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01885195, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in